Market Challenges And Opportunities

Rising prevalence of prostate cancer is expected to boost growth of the brachytherapy market

Rising number of prostate cancer cases are majorly driving growth of the brachytherapy market. According to the American Cancer Society, as of 2017, around 161,370 people are estimated to be diagnosed with prostate cancer and around 26,730 deaths are recorded due to prostate cancer in the U.S. Prostate cancer is the third-leading cause of death for men in the U.S. The other factors that are contributing to growth of the brachytherapy market include, rising adoption of high dose rate brachytherapy and increasing prevalence of obesity. However, side effects associated with radiation therapy such as hair loss, fatigue, appetite, and nausea are expected to hinder growth of the brachytherapy market.

The innovative breast microseed treatment for breast cancer is expected to propel growth of the brachytherapy market in North America

On the basis of region, the global brachytherapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position, owing to the rising adoption of breast microseed treatment for breast cancer. Using brachytherapy, breast microseed treatment involves the precise placement of radioactive seeds in the breast that slowly release the prescribed dose safely over the period. This is an innovative treatment for early stage breast cancer, which affects 1 in 8 women in North America. For instance, According to the Centers for Disease Control and Prevention, in 2014, around 236,968 women and 2,141 men were diagnosed with breast cancer in the U.S.